Trevi Therapeutics, Inc.

NasdaqGM TRVI

Trevi Therapeutics, Inc. Price to Earnings Ratio (P/E) on February 05, 2025

Trevi Therapeutics, Inc. Price to Earnings Ratio (P/E) is NA on February 05, 2025, a NA change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Trevi Therapeutics, Inc. 52-week high Price to Earnings Ratio (P/E) is -3.86 on February 06, 2024, which is NA below the current Price to Earnings Ratio (P/E).
Trevi Therapeutics, Inc. 52-week low Price to Earnings Ratio (P/E) is -9.78 on March 21, 2024, which is NA below the current Price to Earnings Ratio (P/E).
Trevi Therapeutics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -6.31.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGM: TRVI

Trevi Therapeutics, Inc.

CEO	Ms. Jennifer L. Good
IPO Date	May 7, 2019
Location	United States
Headquarters	195 Church Street
Employees	27
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Personal Care

Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Key trends

Past 5 years